STAT News

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.

By STAT News

1 min read
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights